Zymeworks Lifts 2026 Revenue Guidance to $292M After Theravance Deal

Zymeworks Inc. (Nasdaq: ZYME) announced on Sept. 28, 2026 that it completed its acquisition of Theravance Biopharma and issued updated full-year 2026 guidance of $278 million to $292 million in total revenue and $114 million to $128 million in Adjusted EBITDA. Theravance Biopharma shareholders received $17.00 in cash per share at closing. The deal adds YUPELRI (revefenacin) to Zymeworks' portfolio and was financed with a $350 million non-recourse OMERS note plus roughly $217.5 million of Zymeworks' own cash.

Context — why the Theravance Biopharma acquisition matters now

The transaction, first announced on June 29, 2026, converts Zymeworks from a royalty-and-partnership story into a company that also books recurring commercial revenue. The report frames YUPELRI as a durable, recurring source of cash flow meant to fund the company's long-term growth strategy. That distinction matters because biotech investors typically discount pre-commercial pipelines and pay up for predictable cash generation.

Zymeworks said the base case carries a mid-teens internal rate of return, supported mainly by growth in YUPELRI revenues and a smaller contribution from VIBATIV. The company disclosed that its base case assigns no value to the $2.5 billion of Irish tax attributes acquired in the deal. Any future use of those attributes would therefore be additional upside, the company said.

Company management tied the deal's logic to its existing infrastructure. Chief Business Officer Scott Platshon said Zymeworks can create value through its R&D and operational base, including the ability to use the acquired Irish tax attributes alongside ongoing R&D work in Ireland, advantages he said are not readily available to traditional royalty-focused buyers.

The update lands alongside an FDA approval. Zymeworks received U.S. Food and Drug Administration approval of Ziihera (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma on Aug. 25, 2026. The company said the approval and the acquisition together prompted it to shift to financial metrics it believes better frame operating performance.

Data — what the Zymeworks numbers show

The headline figures are the 2026 guidance ranges. Total revenue is guided to $278 million to $292 million, and Adjusted EBITDA to $114 million to $128 million, both excluding any future transactions. Adjusted EBITDA is a non-GAAP measure; the company excludes income tax, interest income and expense, depreciation and amortization, other non-operating items, and share-based compensation from net income or loss.

On the acquired asset, first-half 2026 total YUPELRI sales of $133.1 million generated $38.4 million in collaboration revenue to Theravance Biopharma. Zymeworks is entitled to a 35% share of net U.S. profits from YUPELRI through Theravance's collaboration with Viatris, plus royalties on net sales outside the United States. Hospital sales of YUPELRI grew 25% in the second quarter of 2026.

Item	Figure
2026 revenue guidance	$278M-$292M
2026 Adjusted EBITDA guidance	$114M-$128M
Per-share cash to Theravance holders	$17.00
OMERS non-recourse note	$350M
Zymeworks cash used	~$217.5M
Irish tax attributes	$2.5B

On capital return, the board authorized a 2026 repurchase program of up to $125.0 million in May 2026. Zymeworks has used roughly $49.3 million of that authorization to buy 1,971,454 shares at an average price of $25.04. Since starting buybacks in August 2024, the company has spent $211.6 million to reacquire 10,571,316 shares at an average price of $20.02. About 71.2 million common shares were outstanding as of Sept. 14, 2026.

Analysis — what it means for markets, sectors and tickers

The structure of the financing is the part peers will copy or avoid. Zymeworks funded the purchase with a $350 million non-dilutive, non-recourse note from OMERS, assigning 75% of YUPELRI profit-share cash flows to service the debt. Until the note is repaid, the company keeps the remaining 25%; after repayment, it retains 100% of those cash flows. That keeps equity dilution out of the story, which matters for a shareholder base that has watched the company complete its last public equity offering in January 2022, with no current plans for additional issuances.

The counter-argument sits in the asset itself. YUPELRI is a single commercial product whose economics depend on the Viatris collaboration and hospital-channel growth. The report notes hospital channel growth remains a key driver of expansion in the community setting. If that growth stalls, the base-case mid-teens IRR weakens, and the 75% cash-flow assignment to OMERS means equity holders absorb the shortfall first.

A second call option rests on a contingent payment. Zymeworks expects a potential $100 million milestone tied to TRELEGY ELLIPTA in the first quarter of 2027, assuming milestone conditions are met, which would offset the cash outlay on the purchase price. The company also expects to recognize a tax liability for an uncertain tax position; if the applicable audit period expires in October 2026, the liability may reverse into a non-cash income tax benefit in the fourth quarter of 2026.

On ampreloxetine, a Theravance designee will seek to license, divest or otherwise monetize the asset within one year of closing, with no additional resources expected from Zymeworks. Economics from any such deal are shared 20/80 between Zymeworks and Theravance Biopharma shareholders. Positioning follows the story: income-oriented holders get a commercial cash stream, while pipeline-focused holders keep exposure to Ziihera and pasritamig.

Outlook — what to watch next

Three dated items anchor the next two quarters. The preliminary purchase accounting will appear in the Form 10-Q for the quarter ending Sept. 30, 2026, expected to be filed in November 2026. The uncertain tax position may reverse upon expiration of the applicable audit period in October 2026, producing a non-cash income tax benefit in the fourth quarter. The potential $100 million TRELEGY ELLIPTA milestone payment is expected in the first quarter of 2027, assuming the applicable commercial sales milestone is achieved by Dec. 31, 2026.

Investors also have the integration markers to track. Zymeworks intends to retain the current commercial organization handling YUPELRI hospital promotion and plans to hire a seasoned pharmaceutical executive to lead Theravance Biopharma's commercial operations. Stuart Knight becomes Executive Vice President and Chief Information Officer, and Jesse Fecker joins as Vice President, Intellectual Property. Management hosts a conference call at 8:30 am Eastern Time.

Frequently Asked Questions

What does the Zymeworks guidance mean for retail investors?

The guidance resets how the company is valued. Revenue of $278 million to $292 million and Adjusted EBITDA of $114 million to $128 million give a commercial-scale frame that a pipeline-only biotech does not have. Because Adjusted EBITDA strips out interest, taxes, depreciation, amortization and share-based compensation, it shows cash-generating capacity before financing costs. The $350 million OMERS note's interest is excluded, so investors should weigh debt service separately when judging the numbers.

What happens next for Zymeworks shareholders?

Buybacks continue under the $125.0 million authorization, with about $49.3 million used as of Sept. 28, 2026. The Form 10-Q in November will show preliminary purchase accounting, including YUPELRI as the principal identifiable intangible asset, amortized through the expected loss-of-exclusivity period, with any remainder recorded as goodwill. A possible fourth-quarter tax benefit and the first-quarter 2027 TRELEGY milestone are the next cash events.

Why did Zymeworks change its financial guidance framework?

The company said the acquisition and the Aug. 25, 2026 FDA approval of Ziihera made its prior metrics less suitable for evaluating operating performance. It now leads with total revenue and Adjusted EBITDA. Acquisition and restructuring-related costs, excluding capitalized costs tied to the OMERS financing, are estimated at $25 million to $30 million. The company said the guidance excludes the impact of any future transactions.

Bottom Line

Zymeworks now books YUPELRI cash flow against $278 million to $292 million in 2026 revenue, with a $100 million TRELEGY milestone as the next swing factor.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.